Similar Papers

Paper Title
Journal
Date
Author
Tissue is the issue: Chemotherapy response score (CRS) is most predictive of response to neoadjuvant chemotherapy in advanced, high grade serous ovarian cancer (HGSOC) (488)
Abbey Knickerbocker ... Tilley Jenkins Vogel
Gynecologic Oncology | VOL. 166
Abbey Knickerbocker, et. al.Abbey Knickerbocker ... Tilley Jenkins Vogel
01 Aug 2022
Abstract A28: Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtypes and change in treatment course
Hisamitsu Takaya ... Hidekatsu Nakai
Clinical Cancer Research | VOL. 26
Hisamitsu Takaya, et. al.Hisamitsu Takaya ... Hidekatsu Nakai
01 Jul 2020
Abstract A074: Correlation of homologous recombination deficiency (HRD) status by BROCA-HR sequencing with response to combination cediranib and olaparib in relapsed ovarian cancer
Joyce F Liu ... Jennifer Curtis
Molecular Cancer Therapeutics | VOL. 18
Joyce F Liu, et. al.Joyce F Liu ... Jennifer Curtis
01 Dec 2019
Frequency of homologous recombination deficiency in a large community-based cohort of epithelial ovarian cancer cases (597)
Nicole Kretzer ... Charles Drescher
Gynecologic Oncology | VOL. 166
Nicole Kretzer, et. al.Nicole Kretzer ... Charles Drescher
01 Aug 2022
View more papers

More From: Gynecologic Oncology

Paper Title
Journal
Date
Author
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258.
Aine Clements ... Angeles Alvarez Secord
Gynecologic oncology | VOL. 193
Aine Clements, et. al.Aine Clements ... Angeles Alvarez Secord
23 Jan 2025
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results.
David M O'Malley ... Michele Maio
Gynecologic oncology | VOL. 193
David M O'Malley, et. al.David M O'Malley ... Michele Maio
22 Jan 2025
Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma.
Michael D Toboni ... Nathaniel Jones
Gynecologic oncology | VOL. 193
Michael D Toboni, et. al.Michael D Toboni ... Nathaniel Jones
20 Jan 2025
Cost-effectiveness of an additional hysterectomy after initially conservative treatment for cervical adenocarcinoma in situ.
M Schaafsma ... N.E Van Trommel
Gynecologic oncology | VOL. 193
M Schaafsma, et. al.M Schaafsma ... N.E Van Trommel
17 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.